First Tracks climbs on ‘impressive’ celiac study data

Data ReadoutpositivePositive

AI Analysis

Summary

First Tracks reported initial study findings for its CD122-targeting celiac disease drug, which analysts viewed as impressive and suggesting potential as a 'pipeline-in-a-product'.

Clinical Trial Data

Outcome Details

Initial study findings described as 'impressive' by analysts, targeting CD122 protein with potential 'pipeline-in-a-product' profile

Importance:6/10

Sentiment:

0.75

celiac diseaseCD122clinical datapositive trial results

Related Companies

$TRAX

Read the original article

Published by BioPharma Dive on October 12, 2026 9:26 PM

Read Original